April 30, 2021
Appendix 4C Quarterly Activity Report
Mesoblast Operational and Financial Highlights for Quarter Ended March 31, 2021NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) — Mesoblast Limited…
Pharmaceuticals, Biotechnology and Life Sciences
Mesoblast Operational and Financial Highlights for Quarter Ended March 31, 2021NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) — Mesoblast Limited…
CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (NASDAQ: HOWL), an innovative biopharmaceutical company pioneering the development…
London, UK, 30 April 2021 (GLOBE NEWSWIRE) — COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care…
NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory…
Remestemcel-L reduced mortality through 60 days in the pre-specified population under 65 years oldIn these patients the benefit was further…
OXFORD, United Kingdom, April 29, 2021 (GLOBE NEWSWIRE) — Vaccitech plc (“Vaccitech”) (Nasdaq: VACC), a clinical-stage biopharmaceutical company engaged in…
RAPIDe-1 clinical trial enrolling, evaluating PHVS416 as an oral on-demand therapy for HAEOpen IND for the prophylactic evaluation of PHVS416Strong…
TORONTO, April 29, 2021 (GLOBE NEWSWIRE) — Jack Burnett, President and a director of Ramm Pharma Corp. (“Ramm” or, the…
Fifth Treatment Arm to Evaluate Safety of ELX-02 in Combination with Kalydeco (ivacaftor) Reaffirmed Data Readout for First Four Treatment…
THE WOODLANDS, Texas, April 29, 2021 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its first quarter 2021…